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Collegium Medicum of Nicolaus Copernicus University, Department of Endocrinology and Diabetology, Bydgoszcz, Poland
Jan Biziel’s University Hospital, Division of Vascular Diseases and Internal Medicine, Bydgoszcz, Poland
 i g  h  l  i g  h  t  s
We  examine  the  association  between  serotonin-related  gene  polymorphisms  and  the  occurrence  of  depressive  symptoms.
The  experimental  group  consists  of  obese  patients.
For  the depressive  symptoms  measurement  we  use the Beck  Depression  Inventory  (BDI)  and  Hamilton  Depression  Scale  (HAM-D).
39%  of  patients  are diagnosed  with depressive  symptoms.
There  are  no significant  associations  between  5-HT2A and  5-HTT  gene  polymorphisms  and  depressive  symptoms.
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a  b  s  t  r  a  c  t
As  overweight  and  obesity  are  a growing  problem  in  industrialized  societies,  they  become  a  main  focus
of  many  studies.  The  aim  of  this  study was  to determine  whether  there  is  an  association  between  the
occurrence  of  polymorphisms  in serotonin-related  genes  and  the  prevalence  of  depressive  symptoms
in  obese  patients.  Two  polymorphisms  were  tested:  a 44-bp  insertion/deletion  in  the  serotonin  trans-
porter  (SERT)  gene  and  a single-nucleotide  variation  (1438G/A)  in  the  serotonin  2A  receptor  (5-HT2A)
gene.  The  study  involved  180 patients  (41 men;  139  women)  previously  diagnosed  as  obese.  All  patients
were  subjected  to  clinical,  biochemical,  and neuropsychological  evaluation  and  genotyping.  Amplifica-
tion  of the gene  fragments  was  obtained  by  the  polymerase  chain  reaction  (PCR)  method.  Products  of
the  genotyping  were  separated  via  electrophoresis.  The  intensity  of  depressive  symptoms  was  measured
using  the  Beck  Depression  Inventory  (BDI)  and  Hamilton  Depression  Scale  (HAM-D).  Clinically  relevant
depressive  symptoms  were  diagnosed  in  39%  of  subjects.  The  lowest  intensities  of  depressive  symptoms
were  ascertained  in the  group with  the  least  advanced  obesity,  but  this  trend  was  statistically  insignifi-
cant.  Small  differences  were  observed  in  obesity  indicators  among  three  groups  of  patients  with  various
genotypes  of  the  SERT  gene,  but  these  differences  were  also  statistically  insignificant.  Furthermore,  in
the context  of  the  intensity  of depressive  symptoms,  no  significant  associations  were  observed  in  these
two groups.  Furthermore,  no  statistically  significant  differences  were  observed  among  specific  obesity
parameters  and  intensity  of depressive  symptoms  as a function  of  the  5-HT2A gene polymorphism.  To
conclude,  depressive  symptoms  were  prevalent  in  obese  participants:  39%  of subjects  experienced  symp-
toms  of clinical  relevance.  However,  no significant  associations  were  observed  between  5-HT2A and  SERT
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1. IntroductionThe highest prevalence of obesity affects industrialized coun-
tries and societies, in which high-calorie diets are widespread. In
Poland, the number of people living with this problem is increasing.
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evealed that the percentage of obese women increased from 28%
o 29% and that of obese men  increased from 18.6% to 22.4% over
his time period [1].
Overweight and obesity are also correlated with the occurrence
f depressive symptoms. Prospective observational research has
hown that occurrence of depression predicts the development of
besity, and also that the occurrence of obesity is a factor in the
evelopment of depression [2,3]. Data collected over the course of
 national health program conducted in the USA from 2005 to 2006
evealed that BMI  positively correlates with mild and moderate
epressive symptoms, as well as with major depression, defined as
aving a score of ≥10 or meeting the Diagnostic and Statistical Man-
al of Mental Disorders, 4th edition (DSM-IV) diagnostic criteria
or major depression on the nine-item Patient Health Question-
aire (PHQ-9). The increase in depressive symptoms as a function
f weight starts at a BMI  of 30 kg/m [2,4].
A large body of research indicates that serotonergic trans-
ission plays a role in eating disorders. In humans, serotonin
nd its agonists cause moderation of food ingestion, weight loss,
nd increased energy expenditure. The activity of the serotonin
ransporter (SERT) is negatively correlated with BMI  [5], possi-
ly explaining the effectiveness of selective serotonin reuptake
nhibitors (SSRI) for the treatment of obesity [6,7].
The gene encoding SERT is located on the long arm of chromo-
ome 17 (17q11.1–17q12). Polymorphisms in the transcriptional
egulatory region of this gene (5-HTTLPR: SERT gene-linked poly-
orphic region)  involve a region of variable length that is rich in
uanine–cytosine pairs. The absence or presence of a 44-bp frag-
ent in this region results in the short (S) or long (L) variant,
espectively; these variants differ in gene promoter activity [8].
he S-allele is linked to lower baseline transcriptional activity of
he SERT gene, resulting in lower efficiency of serotonin reuptake
9,10]. To date, it remains unclear whether the 5-HTTLPR polymor-
hism is related to obesity.
The gene encoding the serotonin 2A receptor (5-HT2A) is located
n the long arm of chromosome 13 (13q14–q21). The most
ommonly investigated polymorphism of this gene is a single-
ucleotide variation, 1438 G/A, in the promoter. Several studies
ave investigated the possible role of this polymorphism in obe-
ity, but the results are ambiguous. Perez-Cornago et al. determined
hat DNA hypermethylation of 5-HT2A is associated with a worse
esponse to a weight loss intervention in subjects with metabolic
yndrome [11].
Both of these polymorphisms have also been investigated in
he context of their association with depressive symptoms. In a
cottish population, the S-allele positively correlated with unipo-
ar disorder[12]; however, another study showed that the L-allele is
ssociated with this disease [13]. A meta-analysis published in 2004
evealed a statistically significant association between the S-allele
nd unipolar disorder [14]. Analysis of the 1438G/A polymorphism
id not reveal any significant correlation with the occurrence of
ajor depression [15]. However, in a group of 67 persons with
easonal depression, the A-allele was more prevalent [16].
. The aim of the study
We  sought to assess the association between polymorphisms in
erotonin-related genes (5-HT2A and SERT) and the occurrence of
epressive symptoms in obese patients.
. MethodsThe study involved 180 patients (139 women) of Polish nation-
lity and Caucasian ethnicity, aged 18–73 years (mean, 43.7 ± 7.8).
emographic factors are shown in Table 1. The subjects were Letters 586 (2015) 31–35
diagnosed as obese (BMI > 30 kg/m2) and they were recruited
from population hospitalized in Department of Endocrinology and
Diabetology of Collegium Medicum of the Nicolaus Copernicus Uni-
versity (NCU) due to obesity. Patients with addictions or severe
somatic, psychiatric, or neurological disorders were excluded, as
were patients with secondary obesity. Permission for the study was
obtained from the Bioethical Commission of the NCU, Collegium
Medicum in Bydgoszcz (No. 533/2008). The subjects demonstrated
their willingness to participate in the project by signing the
Informed Consent Form.
3.1. Assessments
The first stage of the study was  the clinical assessment, which
consisted of obtaining a medical history and performing a phys-
ical examination. Aspects of obesity and psychological disorders
mentioned in the medical history were emphasized. Metric mea-
surements were taken of body weight, waist circumference, and
hip circumference; waist-hip ratio (WHR) was  also calculated.
The next step was  assessment of the intensity of depressive
symptoms. For this purpose, The Beck Depression Inventory (BDI)
and the Hamilton Depression Rating Scale (HAM-D) were used.
According to the BDI, patients scoring 12 or more points were
diagnosed as having clinically important symptoms of depression.
HAM-D is a multiple-choice questionnaire that is useful for mea-
suring levels of depression among patients. The questionnaire is
filled in by the clinician; therefore, it is an objective tool for mea-
suring the intensity of depressive symptoms. HAM-D, which was
designed for adults, defines the level of observed depressive symp-
toms, including low mood, insomnia, anxiety, and weight loss.
3.2. Isolation of genetic material
7–10 ml  of peripheral blood was collected and mixed with 0.5 ml
of 0.5 M ethylenediaminetetraacetic acid (EDTA), then frozen in
liquid nitrogen and stored at −80 ◦C until isolation. The isolation
procedure was  followed using fast isolation procedure by Lahiri
and Schnabel [17] and stored at −20 ◦C.
3.3. Genotype analysis
5-HT2A gene promoter region and SERT gene fragments where
amplified using the polymerase chain reaction (PCR) method with
the following protocol: initial denaturation at 95 ◦C for 5 min, 30
cycles of denaturation at 95 ◦C for 1 min, annealing at 58 ◦C for
1 min, elongation at 72 ◦C for 1 min, and final extension at 72 ◦C
for 2 min. The reaction mixture contained 0.2 U of Taq polymerase
(Fermentas), 5 pmol of each primer, 1 × (NH4) 2SO4 buffer, 4 mmol
dNTP mixture, 100–200 ng of matrix DNA, 1.5 mM MgCl2 and H2O
to final volume of 20 l.
Primers’ sequences for 5-HT2A were: F
5’-ACGAAGGGACTCCTGGTTTC-3’ and R 5’-
CTGGGTGGGATATTTCTGCT-3’ [18]. Amplified product of 515 bp
length (∼100 ng) was digested overnight with 0.2 U of HpaII
restriction enzyme (Fermentas) at 37 ◦C. Amplicons with −1438G
allele were cut into 331 bp and 184 bp fragments, while those with
−1438A remained undigested. The fragments were separated via
electrophoresis in 3% agarose gel containing ethidium bromide
and visualized under UV illumination with O’RangeRulerTM 50 bp
DNA Ladder (Fermentas) as DNA length marker (Fig. 1).
Primers’ sequences for SERT were:
5′-GGCGTTGCCGCTCTGAATGC-3′ and 5′-
GAGGGACTGAGCTGGACAACCAC-3′ [19]. Amplified products
of 529 and 485 bp, corresponding to L and S allele respectively,
were separated via electrophoresis in 2% agarose gel containing
ethidium bromide and visualized under UV illumination with
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Table  1
Demographic and clinical characteristics of the study participants undefined.
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BMI: body mass index; BDI: Beck Depression Inventory; HAM-D: Hamilton Depression Sc
Fig. 1. Representative photo of the digested 5-HT2A PCR products depending on
the genotype: AA–only 515 bp band; G/A–515, 331 and 184 bp bands; GG–331 and






















in subgroups comprising male and female subjects (Table 2).
In addition, we  examined the correlation between the L/S poly-
morphism and excessive body mass. (Table 2) presents the mean
Table 2
BDI, HAM-D and BMI  results in relation to polymorphism L/S (SLC6A4) of the SERT
gene.
TOTAL





















































































BMI  48.9 43.9 51.5 0.42ig. 2. Representative photo of separated SERT PCR products depending on the
enotype: LL–only 529 bp band; S/S 485 bp band; L/S–529 and 458 bp bands M-DNA
adder.
’RangeRulerTM 50 bp DNA Ladder (Fermentas) as DNA length
arker (Fig. 2).
.4. Statistical analysis
STATISTICA 9.0 was used for statistical analyses. The distribu-
ion of variables was analyzed using the Shapiro–Wilk test, which
ndicated that the variables were non-parametric. To assess the sig-
ificance of the differences between groups, the Mann–Whitney
 test was conducted for comparisons between two groups and
he Kruskal–Wallis one-way analysis of variance by ranks test was
sed for comparisons among three groups. The R-Spearman test
as used to determine correlations between variables. The com-
uter program ‘Utility Programs for Analysis of Genetic Linkage’
Copyright© 1988J. Tot) was utilized to test the goodness of fit
f the genotypes to Hardy–Weinberg equilibrium. A p-value > 0.05
ndicates agreement with Hardy–Weinberg equilibrium.
. ResultsThe Mann–Whitney U test was performed to determine whether
he BMI  parameter differed significantly between male and female
ubjects. The mean BMI  value was slightly higher in the male pop-
lation, but this difference was not statistically significant. to 44,7] [8,5 to 15,7] [3,6 to 10,0]
ale.
The intensities of depressive symptoms determined by the
BDI and HAM-D scales were highly positively correlated in both
women (p = 1E-05) and men  (p = 0.0001). Clinically relevant depres-
sive symptoms were diagnosed in 39% of subjects. Because the data
were non-parametric we calculated the R-Spearman rank correla-
tion coefficient to investigate the correlation between age and BMI;
these values were positively correlated (r = 0.329; p = 0.000022).
No relevant correlations among age and BDI/HAM-D scores were
observed. The lowest intensities of depressive symptoms (as mea-
sured by the BDI) were observed in the group with the lowest level
of obesity, but this trend was not statistically significant.
Regarding the L/S (SLC6A4) polymorphism of the SERT gene, we
used both the BDI and HAM-D to measure the intensity of depres-






Values are expressed as the median (range). [95%CI] – 95% confidence interval; BDI:
Beck Depression Inventory; HAM-D: Hamilton Depression Scale.
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Table 3
BDI, HAM-D and BMI results in relation to polymorphism 1438 G/A of the 5-HT2A
gene.
TOTAL

























































































































BDI: Beck Depression Inventory; HAM-D: Hamilton Depression Scale; BMI: Body
ass Index.
alues of the parameters describing obesity in three subgroups:
/L and S/S homozygotes and L/S heterozygotes. Analysis of these
esults indicated that there were no statistically significant differ-
nces among the three subgroups, BMI  oscillated around similar
alues regardless of the allele type.
Among obese females, the associations between L-allele car-
ier and S-allele homozygote status and the intensity of depressive
ymptoms (measured with the BDI) were likewise not significant
Table 2). In L/L and L/S females the intensity of depressive symp-
oms was 9.0, and among S/S females it was 15.5, with the p-value
f 0.077.
The most frequently studied polymorphism of the 5-HT2A gene
s the 1438 G/A promoter polymorphism. Therefore, we next inves-
igated whether the occurrence of obesity differed among A/A and
/G homozygotes and G/A heterozygotes (in subgroups of women
nd men) (Table 3). However, the differences were not statisti-
ally relevant; BMI  oscillated around similar values regardless of
he allele type.
In addition, we investigated the association between poly-
orphisms in the 5-HT2A gene and the intensity of depressive
ymptoms as measured by both BDI and HAM-D (Table 3). This
nalysis did not detect any significant differences in the inten-
ity of depression in association with the 5-HT2A gene 1438 G/A
olymorphism.. Discussion
Overweight and obesity have become serious problems in
ecent years; therefore, identifying the causes and developing new Letters 586 (2015) 31–35
treatments are important scientific goals. Furthermore, psycholog-
ical issues are a key aspect of eating disorders.
Many studies show that the most common problem affect-
ing overweight and obese people is depression [2–4,20]. Here, we
confirmed that the prevalence of depression in a cohort of obese
patients was 39%. It is in agreement with previous studies which
likewise indicated high prevalence of depression in obese subjects
[2]. Previous studies report a correlation between perturbations of
the serotoninergic system, obesity, and depression; consistent with
this, serotoninergic antidepressants have been used successfully to
treat some cases of obesity [21].
On the basis of these earlier findings, one of the main goals of
the present study was to assess the interplay between polymor-
phisms in genes related to neurotransmitter activity, parameters of
obesity, and depressive symptoms; certain interdependences were
identified.
Previous studies [8,22,23] on the association between the L/S
5-HTTLPR polymorphism and obesity yielded conflicting results.
Similarly, the results presented here do not demonstrate a specific
correlation between BMI  and L/S 5-HTTLPR. Therefore, this question
requires additional study in other groups of obese subjects.
Studies conducted nearly 20 years ago suggest a correlation
between the L-allele and unipolar disease [12,13]. However, a sub-
sequent meta-analysis of three studies indicates that the S-allele is
associated with unipolar disease [24]. The results presented herein
are different from those of previous studies, which suggested that
the S-allele is associated with a greater predisposition to depression
[25]. Also in recent study Schulz et al. observed relevant correla-
tion between S-allele and depression measured by Short Geriatric
Depression Scale in group of 606 individuals [26].
Here, we  observed no associations between 5-HTTLPR genotype
and the intensity of depressive symptoms (as measured by BDI and
HAM-D). This finding suggests that in these patients polymorphism
of the serotonin transporter gene is not the most significant factor
leading to depression.
As to the 1438G/A polymorphism in the serotonin 2A recep-
tor, we  observed no significant difference in obesity indicators in
subjects carrying this allele. Similarly, no such differences were
detected in a family study conducted in a Spanish population
[29].
Likewise, we did not observe an association between the G and
A alleles and the intensity of depressive symptoms in obese sub-
jects. Therefore, it is likely that polymorphism of the 5-HT2A gene
does not play a significant role in the etiology of depression in
obese people. Similar results were obtained in several studies of
affective diseases assessed in two  meta-analyses [15,16], in which
major depression, unipolar and bipolar disorders ware diagnosed
according to a standard diagnostic criteria (DSM, ICD).
The findings of global studies are not uniform: Japanese authors
have demonstrated a statistically significant association between
the 5-HT2A A/G polymorphism and the intensity of depressive
symptoms (as measured by the MADRS scale) [30].
The present results suggest, at least in this specific population,
that it is unlikely that polymorphisms in the SERT and 5-HT2A genes
are significantly correlated with the intensity of depressive symp-
toms in obese subjects or with obesity itself. Thus, the results reflect
the enormous complexity of the problem of obesity and depression.
We  must continue searching for the genetic mechanisms respon-
sible for depressive symptoms in these patients.Conflict of interest
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